Key Points
- Michael Jon Brown sold 1,700 shares of DexCom on April 15 at an average price of $63.04 under a pre‑arranged Rule 10b5‑1 plan, a 1.51% reduction to his position (now 111,204 shares); the sale was disclosed to the SEC.
- DexCom beat quarterly estimates, reporting $0.68 EPS vs. $0.65 expected and $1.26B revenue (+13.1% YoY), with a 17.94% net margin and 32.12% ROE.
- Wall Street is largely positive with a consensus "Moderate Buy" and an average price target of $86.50, though analysts and articles warn of pricing pressure and near‑term margin risks that could temper upside.
DexCom, Inc. (NASDAQ:DXCM - Get Free Report) EVP Michael Jon Brown sold 1,700 shares of the business's stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $63.04, for a total transaction of $107,168.00. Following the sale, the executive vice president directly owned 111,204 shares of the company's stock, valued at approximately $7,010,300.16. The trade was a 1.51% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Michael Jon Brown also recently made the following trade(s):
- On Monday, March 16th, Michael Jon Brown sold 1,700 shares of DexCom stock. The shares were sold at an average price of $64.85, for a total transaction of $110,245.00.
DexCom Trading Down 0.5%
Shares of DXCM stock opened at $61.23 on Friday. DexCom, Inc. has a 1 year low of $54.11 and a 1 year high of $89.98. The firm has a fifty day moving average price of $67.48 and a 200-day moving average price of $66.75. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.88 and a quick ratio of 1.59. The company has a market cap of $23.56 billion, a price-to-earnings ratio of 29.16, a PEG ratio of 1.20 and a beta of 1.55.
DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings data on Thursday, February 12th. The medical device company reported $0.68 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.65 by $0.03. DexCom had a net margin of 17.94% and a return on equity of 32.12%. The firm had revenue of $1.26 billion during the quarter, compared to the consensus estimate of $1.25 billion. During the same quarter in the previous year, the firm posted $0.45 EPS. The company's revenue for the quarter was up 13.1% compared to the same quarter last year. As a group, equities analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current year.
Key Stories Impacting DexCom
Here are the key news stories impacting DexCom this week:
- Positive Sentiment: Zacks upgraded DXCM to a Rank #2 (Buy), signaling improved earnings expectations that can attract short‑term buying. DexCom (DXCM) Upgraded to Buy: Here's Why
- Positive Sentiment: BTIG reaffirmed its Buy rating on DexCom, keeping institutional support for the name and reinforcing the bullish analyst narrative. BTIG Keeps Their Buy Rating on Dexcom (DXCM)
- Positive Sentiment: Recent coverage (Yahoo/Zacks) urges adding DXCM based on expanding continuous glucose monitoring (CGM) market share, the G7 product rollout and accelerating global adoption — all positive medium‑to‑long‑term growth drivers. Here's Why You Should Add DexCom Stock to Your Portfolio Now
- Neutral Sentiment: “3 Reasons Investors Love DexCom” pieces highlight the company’s durable market position and product roadmap but note the stock’s recent underperformance versus the S&P, providing mixed context for investors weighing timing. 3 Reasons Investors Love DexCom (DXCM)
- Neutral Sentiment: Michael Jon Brown, DexCom EVP, sold 1,700 shares under a pre‑arranged Rule 10b5‑1 plan; the sale is small relative to his total holding and was disclosed to the SEC — typically not taken as a negative signal by itself. Michael Jon Brown Insider Sale
- Neutral Sentiment: The Motley Fool piece listing healthcare names that could outperform may include structural tailwinds for DXCM, but it’s a long‑term thematic story rather than near‑term price catalyst. 2 Healthcare Stocks That Could Outperform the Market Over the Next Decade
- Negative Sentiment: Multiple articles and analysts flag pricing pressure and near‑term margin headwinds (from reimbursement and competitive pricing), which could compress margins even as revenue grows — a key reason some investors remain cautious. Here's Why You Should Add DexCom Stock to Your Portfolio Now (risks noted)
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the company. Reflection Asset Management purchased a new position in shares of DexCom during the 4th quarter valued at $25,000. SJS Investment Consulting Inc. lifted its stake in shares of DexCom by 4,800.0% during the 3rd quarter. SJS Investment Consulting Inc. now owns 392 shares of the medical device company's stock valued at $26,000 after buying an additional 384 shares in the last quarter. Financial Consulate Inc. purchased a new position in shares of DexCom during the 3rd quarter valued at $29,000. CVA Family Office LLC lifted its stake in shares of DexCom by 48.5% during the 4th quarter. CVA Family Office LLC now owns 450 shares of the medical device company's stock valued at $30,000 after buying an additional 147 shares in the last quarter. Finally, MCF Advisors LLC purchased a new position in shares of DexCom during the 4th quarter valued at $32,000. Hedge funds and other institutional investors own 97.75% of the company's stock.
Wall Street Analysts Forecast Growth
DXCM has been the subject of a number of recent research reports. BTIG Research reissued a "buy" rating and set a $85.00 price objective on shares of DexCom in a research report on Monday, March 9th. Morgan Stanley reissued an "overweight" rating on shares of DexCom in a research report on Monday, January 12th. Canaccord Genuity Group set a $95.00 price objective on shares of DexCom and gave the company a "buy" rating in a research report on Friday, February 13th. Sanford C. Bernstein reissued an "outperform" rating and set a $86.00 price objective (up from $84.00) on shares of DexCom in a research report on Friday, January 9th. Finally, Weiss Ratings upgraded shares of DexCom from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Wednesday, March 4th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, DexCom presently has a consensus rating of "Moderate Buy" and an average price target of $86.50.
Get Our Latest Analysis on DXCM
DexCom Company Profile
(
Get Free Report)
DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company's offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.
Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
